Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'NC100150 Injection' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'NC100150 Injection' found in 1 term [] and 4 definitions []
1 - 5 (of 5)     
Result Pages : [1]
MRI Resources 
Liver Imaging - Patient Information - Veterinary MRI - RIS - Abdominal Imaging - MRI Accidents
 
NC100150 InjectionInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Short name: NC100150, PEG-feron, generic name: Feruglose, preliminary trade name: Clariscan™(1)
NC100150 injection is the code name for an USPIO (ultrasmall superparamagnetic iron oxide) MRI contrast agent under development. Microvessel permeability depends on functional and morphologic characteristics of cancer vessels and on physicochemical properties of the injected contrast medium molecule.
USPIO particles have a favorable pharmacological and tolerance profile and are being tested clinically of the potential for the quantitative characterization of tumor microvasculature and specifically for measures of the microvessel permeability. Iron-based products take advantage of their large molecular size, which prevents diffusion into body tissues. These agents are disposed of by the liver and spleen as particulate matter.
NC100150 Injection (Nycomed Amersham, Amersham Health ) consists of USPIO particles that are composed of single crystals (4- to 7-nm diameter) and stabilized with a carbohydrate polyethylene glycol (PEG) coat. The iron oxide particles have to be suspended in an isotonic glucose solution. The final diameter of an USPIO particle is approximately 20 nm. Blood pool half-life is more than two hours in humans; the particles are taken up by the mononuclear phagocyte system and distributed mainly to the liver and spleen.
NC100150 would compete with the contrast agents Ferumoxytol from AMAG Pharmaceuticals, Inc. and Vasovist™ from EPIX Pharmaceuticals, Inc., but at this time the development of NC100150 Injection is discontinued.


1. IMPORTANT: The trade name Clariscan™ planned to be used at the time of Amersham Health is reused (since 2017) for a contrast agent developed by GE Healthcare. The newly developed Clariscan™ by GE Healthcare is a totally different contrast agent with first approvals in March of 2017. Please read Clariscan™.
spacer
 
• Share the entry 'NC100150 Injection':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'NC100150 Injection' (2).Open this link in a new window.
MRI Resources 
Corporations - Cochlear Implant - Functional MRI - Implant and Prosthesis - DICOM - Jobs
 
Clariscan™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Clariscan™ (gadoteric acid), a macrocyclic and ionic gadolinium-based contrast agent has newly been approved using the decentralized procedure with marketing authorization in place in Norway. It will be introduced by GE Healthcare to European countries in 2017.


See also: Paramagnetic Contrast Agents, Contrast Medium, Extracellular Fluid Agents, Ionic Intravenous Contrast Agents, Nonionic Intravenous Contrast Agents, Chelate, Adverse Reaction and Nephrogenic Systemic Fibrosis.

See also the related poll result: 'The development of contrast agents in MRI is'

Drug Information and Specification
NAME OF COMPOUND Gadoteric Acid
DEVELOPER GE Healthcare
CENTRAL MOIETY Gadolinium
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY R1 3.1, R2 3.6, B0 = 1.5 Tesla
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 1350 mOsm.kg-1
CONCENTRATION 0.5 mmol /mL
DOSAGE 0.1 mmol/kg / 0.2 ml/kg
INDICATION Brain, spine and associated tissues
PRESENTATIONS Glass vial 5, 10, 15, 20 mL
Glass bottle 50, 100 mL
Polypropylene bottles 50, 100 mL
Plastic (Crystal Clear Polymer) pre-filled syringes 10, 15, 20 mL
DEVELOPMENT STAGE Sale starts 2017 in Norway, Sweden, UK. Global launch is planned.
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT


[ Clariscan™ was also the name of an contrast agent under development by Amersham Health around the year 2000 which doesn't reach the market: '(An iron-based contrast agent with large molecular size, which prevents diffusion into body tissues and was developed for MR imaging of the liver (taken up by macrophages), tumor microvasculature and microvessel permeability. The blood half live of the particles with 11-20 nm diameter is 3-4 hours. See also NC100150 Injection and Ultrasmall Superparamagnetic Iron Oxide)'.
The new developed Clariscan™ by GE Healthcare is a totally different contrast agent.]
spacer

• View the DATABASE results for 'Clariscan™' (6).Open this link in a new window

 
Further Reading:
  Basics:
SUMMARY OF PRODUCT CHARACTERISTICS
Wednesday, 22 February 2017   by www.mhra.gov.uk    
  News & More:
GE Healthcare expands MRI contrast media product range in Europe with launch of macrocyclic agent ClariscanTM
Wednesday, 1 March 2017   by www.businesswire.com    
MRI Resources 
Knee MRI - Mass Spectrometry - MRI Technician and Technologist Jobs - Patient Information - Mobile MRI - Safety Training
 
Code 7228InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Code 7228, generic name: Ferumoxytol, central moiety: Fe
Code 7228 is the code name for a substance in the development pipeline (AMAG Pharmaceuticals, Inc.) for use as a contrast agent in magnetic resonance angiography (MRA). Ferumoxytol, as a true blood pool agent, resides in the vascular space for an extended period of time and does not leak out into adjacent tissues like currently used gadolinium-based contrast agents. The product is being evaluated in MRA applications for the detection of blood flow in the heart muscle, in exploratory studies for the diagnosis of vulnerable plaque and as a next generation lymph node agent.
Code 7228 is currently in approval phase for use as an iron replacement therapeutic in chronic kidney disease patients receiving erythropoetin.
It is presently contemplated that Ferumoxytol will compete with the contrast agents Vasovist™ from EPIX Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham.

spacer

• View the DATABASE results for 'Code 7228' (4).Open this link in a new window

 
Further Reading:
  Basics:
Ferumoxytol
   by www.amagpharma.com    
MRI Resources 
Shielding - Non-English - Colonography - Services and Supplies - Health - Chemistry
 
MS-325Forum -
related threadsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
MS-325 is the formerly code name of gadofosveset trisodium (new trade name Vasovist). MS-325 belongs to a new class of blood pool agents for magnetic resonance angiography (MRA) to diagnose vascular disease. Gadofosveset trisodium has ten times the signal-enhancing power of existing contrast agents as well as prolonged retention in the blood. This enables the rapid acquisition of high resolution MRA's using standard MRI machines.
Gadofosveset trisodium, which is gadolinium-based, stays in the blood stream as a result of transient binding to albumin. Albumin binding offers an additional benefit beyond localization in the blood pool. The contrast agent begins to spin much more slowly, at the rate albumin spins, causing a relaxivity gain that produces a substantially brighter signal than would be possible with freely circulating gadolinium. MS-325 is an intravascular contrast agent intended for use in MRI as an aid in diagnosing aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease (PVD) or abdominal aortic aneurysm (AAA).
Currently clinical trials completed for peripheral vascular disease and coronary artery disease. Additional trials are also being conducted to evaluate MS-325 as an aid in diagnosing breast cancer and suggested that it might be feasible to combine the use of MS-325, injected during peak stress, with delayed high-resolution imaging to identify myocardial perfusion defects.
Vasovist (MS-325) would compete with the contrast agents Ferumoxytol (Code 7228) from AMAG Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham, but their further development is uncertain.
Partners in development: EPIX Pharmaceuticals, Inc., Mallinckrodt Inc., and Bayer Schering Pharma AG. Bayer Schering Pharma has the worldwide marketing rights for the product.
Formerly known under the Mallinckrodt trademark name, AngioMARK®.
See also Classifications, Characteristics, etc.
spacer

• View the DATABASE results for 'MS-325' (4).Open this link in a new window


• View the NEWS results for 'MS-325' (10).Open this link in a new window.
 
Further Reading:
  News & More:
EPIX Medical's new multimedia Web site features AngioMARK images in 3D
Friday, 5 March 1999
MRI technology combined with contrast agent optimizes diagnosis of cardiovascular disease
1999
MRI Resources 
MRI Accidents - Calculation - Health - NMR - Journals - MRI Physics
 
PEG-feronInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: NC100150, PEG-feron, generic name: Feruglose, preliminary trade name: Clariscan™ (1), central moiety: Fe
An ultrasmall superparamagnetic iron oxide under development as a blood pool agent (MRI contrast agent).
See NC100150 Injection.


1. IMPORTANT: The trade name Clariscan™ planned to be used at the time of Amersham Health is reused (since 2017) for a contrast agent developed by GE Healthcare. The newly developed Clariscan™ by GE Healthcare is a totally different contrast agent with first approvals in March of 2017. Please read Clariscan™.
spacer

• View the DATABASE results for 'PEG-feron' (3).Open this link in a new window

MRI Resources 
Crystallography - Implant and Prosthesis pool - Equipment - Claustrophobia - - PACS
 
     1 - 5 (of 5)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



In 2020 your scanner will probably work with a field strength of :
lower 
1T 
1.5T 
2T 
3T 
7T 
higher 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • 
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 16 January 2019]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]